ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0395

Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA)

Patti Katz1, Mary Nakamura2, Sarah Patterson3 and Katie Stone4, 1University of California San Francisco, San Rafael, CA, 2UCSF/SFVAHCS, San Francisco, CA, 3University of California San Francisco, Pacifica, CA, 4University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: rheumatoid arthritis, sleep

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Self-reported poor sleep is common in RA, but only a few small studies objectively measuring sleep have been conducted in RA. In general population studies, sleep disorders are associated with poor health outcomes relevant to RA, including lower pain thresholds and higher rates of depression, cognitive impairment, systemic inflammation, and cardiovascular events. We report on the prevalence of objectively-measured sleep disturbances in a longitudinal cohort of individuals with RA.

Methods: Data are from a study of sleep disorders in RA (n=133).At baseline, participants underwent 9 nights of home sleep monitoring. For the first 2 nights, participants wore a WatchPAT™ device (Itamar Medical, Ltd). For the next 7 nights, participants wore an actigraph (GT9X, Actigraph Corp., Pensacola, FL).Participants were followed over 18 months with 3 follow-ups at 6-month intervals. At each follow-up, actigraphs were worn for 7-day periods. WatchPAT monitoring was discontinued early due to the COVID-19 pandemic. The WatchPAT estimates the apnea-hypopnea index (AHI), reflecting the number of apnea or hypopnea episodes/hour of sleep, an indication of obstructive sleep apnea (OSA), and levels and timing of oxygen desaturation (O2desat). AHI was categorized as normal-mild OSA (< 15) or moderate-severe OSA (≥15). Actigraphs yielded estimates of time in bed, time asleep, and sleep efficiency (SE, time asleep/time in bed).Acceptable SE was defined as ≥85%.Short sleep time was defined as < 7 hours. Analyses examined the frequency of moderate-high OSA, poor SE, and short sleep.

Results: Mean age was 58 ± 13 years, ~90% female, mean BMI 28 ± 6.Mean disease duration was 16 ± 13 years, self-reported disease activity was relatively low (mean RA Disease Activity Index, RADAI, 3.3 ± 1.9). 31% were currently using glucocorticoids.116 participants had sufficient baseline actigraph data for scoring, 63 completed WatchPAT monitoring, and 58 completed both WatchPAT and actigraph assessments at baseline. Only 9.5% of the sample had normal AHI, while over half had moderate-severe OSA (Table 1).Of those with moderate-severe OSA, fewer than a quarter reported receipt of an OSA diagnosis. 10% had some time at O2desat < 80%; 40% had >30 minutes with O2desat < 90%.From actigraphy, mean SE was 83.8% ± 5.7% at baseline, approximately half of participants had SE < 85%, and over half of participants averaged < 7 hours sleep/night; 18% averaged < 6 hours/night (Table 2).Prevalence of poor SE and short sleep was relatively consistent over measurement periods. In the actigraph cohort, 35% had both poor SE and short sleep, 18% had short sleep only, and 16% had poor SE only (Figure 1).Among those with WatchPAT and actigraph assessments, 22% had combined OSA, poor SE, and short sleep. Only 5% had none of the sleep disorders.

Conclusion: The majority of this RA sample had at least one sleep disturbance. Given the known association of sleep disturbances with poor health outcomes and potential associations with RA-related factors such as inflammation and disordered cytokine profiles, increased awareness of sleep problems among people with RA may be beneficial. If findings are replicated, screening for OSA may be an important addition to routine care for RA.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Katz: None; M. Nakamura: None; S. Patterson: None; K. Stone: None.

To cite this abstract in AMA style:

Katz P, Nakamura M, Patterson S, Stone K. Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-objectively-measured-sleep-disturbance-in-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-objectively-measured-sleep-disturbance-in-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology